Increased levels of Syndecan-1 in serum during acute graft-versus-host disease

Transplantation

Volumn 76, Issue 2, 2003, Pages 423-426

  Seidel, Carina ^a   Ringdén, Olle ^a   Remberger, Mats ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2 RECEPTOR; PROTEOHEPARAN SULFATE; SYNDECAN 1;

ACUTE DISEASE; ADOLESCENT; ADULT; ARTICLE; CELL SURFACE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; EPITHELIUM CELL; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; INTESTINE; LIVER; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SKIN; STEM CELL TRANSPLANTATION;

EID: 0042767994     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000074316.76104.A5     Document Type: Article

References (10)

1. Foley R, Couban S, Walker I, et al. Monitoring soluble interleukin-2 receptor levels in related and unrelated donor allogenic bone marrow transplantation. Bone Marrow Transplant 1998; 21: 769-773.
2. Kim CW, Goldberger OA, Gallo RL, et al. Members of the syndecan family of heparan sulfate proteoglycans are expressed in distinct cell-, tissue-, and development-specific patterns. Mol Biol Cell 1994; 5: 797-805.
3. Ringden O, Horowitz MM, Sondel P, et al. Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? Blood 1993; 81: 1094-1101.
4. Hagglund H, Ringden O, Oman S, et al. A prospective randomized trial of Filgrastim (r-metHuG-CSF) given at different times after unrelated bone marrow transplantation. Bone Marrow Transplant 1999; 24: 831-836.
5. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
6. Seidel C, Sundan A, Hjorth M, et al. Serum syndecan-1; a new independent prognostic marker in multiple myeloma. Blood 2000; 95: 388-392.
7. Carey DJ. Syndecans: multifunctional cell-surface co-receptors. Biochem J 1997; 327: 1-16.
8. Jourdan M, Ferlin M, Legouffe E, et al. The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br J Haematol 1998; 100: 637-646.
9. Subramanian SV, Fitzgerald ML, Bernfield M. Regulated shedding of syndecan-1 and -4 ectodomains by thrombin and growth factor receptor activation. J Biol Chem 1997; 272: 14713-14720.
10. Kato M, Wang H, Kainulainen V, et al. Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nat Med 1998; 4: 691-697.